Seegene, a South Korean molecular diagnostics company, highlighted the importance of screening tests and full genotyping for HPV (Human Papillomavirus), a known cause of cervical cancer in women, while presenting reliable HPV testing solutions at an international conference.
Seegene participated in EUROGIN (European Research Organization on Genital Infection and Neoplasia) 2025, held from March 16 to 19 (local time) in Porto, Portugal. Under the theme “Enhancing the Reliability of HPV Screening,” the company operated an exhibition booth and conducted a related symposium.
EUROGIN, established in Europe in 1993, is an international conference focused on HPV-related infections and cancers. It gathers researchers, clinicians, and experts from around the world each year to share research findings and clinical experiences, with the goal of reducing the incidence and mortality rates of cervical cancer and other HPV-related diseases.
Seegene showcased its leading HPV diagnostic products, including “Allplex™ HPV HR Detection” and “Anyplex™ II HPV HR Detection,” which can simultaneously identify individual genotypes within high-risk groups during cervical cancer screening, and “Allplex™ HPV28 Detection,” which detects 28 distinct genotypes. Through these solutions, Seegene emphasized the value of full genotyping, which enables the detection of not only high-risk HPV genotypes that cause cervical cancer but also other genotypes that may result in benign tumors.
During Seegene’s symposium session on March 16, European clinical experts shared cervical cancer screening strategies implemented in real-world medical practice, highlighting the usefulness and necessity of HPV testing in cervical cancer screening. The session also discussed the benefits of self-sampling, which allows individuals to collect their own samples, making testing more convenient. Self-sampling is expected to drive greater adoption of HPV testing.
Shin Dae-ho, Seegene’s Executive Vice President of Sales and Marketing, said, “Through the HPV testing solutions offered by Seegene, we aim to provide medical professionals with more reliable testing options and effective diagnostics.”
Meanwhile, according to the World Health Organization (WHO), cervical cancer is the fourth most common cancer among women globally and the second leading cause of cancer-related deaths. To eliminate cervical cancer, the WHO has set a “90-70-90” target for 2030, calling on countries to achieve 90% vaccination of girls, 70% screening coverage, and 90% access to appropriate treatment. Through its global “90-70-90” campaign, the WHO continues to underscore the vital importance of HPV screening.
